• Journal of Pharmaceutical Investigation
• /
• 제26권2호
• /
• pp.83-89
• /
• 1996

A reverse-phase HPLC method to determine DL-Carnitine Hydrochloride in pharmaceutical preparation is described. UV absorption derivatives of DL-Carnitine Hydrochloride were formed with p-Bromophenacyl Bromide in an essentially quantitative manner using crown ether as catalyst. The DL-Carnitine-bromophenacyl ester absorbed UV radiation strongly at 254nm, allowing the detection of as small a quantity as 12.5ng of DL-Carnitine Hydrochloride. A linear defection range was $5\;{\times}\;10-8 \;{\sim}\;5\;{\times}\;10-7M$ of DL-Carnitine Hydrochloride. And the linear regression at various drug concentration was =0.999 (n=10). The DL-Carnitine Hydrochloride in pharmaceutical preparation was successfully derivatized and separated from other constituents by reverse phase HPLC with detection at 254 nm.

• Journal of Microbiology and Biotechnology
• /
• 제7권5호
• /
• pp.318-322
• /
• 1997

In order to isolate a microorganism having preferential degradation of D-carnitine from DL-carnitine, a bacterium assimilating D-carnitine as a sole carbon and energy source was isolated from soil by enrichment culture and partially identified as Enterobacter sp. Also, a mutant having lessened L-carnitine decomposition rates was selected with nitrosoguanidine mutagenesis, which led to decrease the specific activities of carnitine dehydrogenase (7.6-fold) and ${\beta}$-hydroxybutyrate dehydrogenase (9.5-fold) as compared to the wild strain. Meanwhile, optimal culture conditions for optical resolution of DL-carnitine were investigated. Under optimal conditions, 3.53 g/l L-carnitine was obtained from 20 g/l DL-carnitine, which corresponded to 35.3% L-carnitine yield and 97.9% optical purity.

• Journal of Microbiology and Biotechnology
• /
• 제8권6호
• /
• pp.601-605
• /
• 1998

For the resolution of L-carnitine from DL-carnitine, resting cells of Enterobacter sp. NH-104, which had a higher capacity of D-carnitine decomposition, were harvested at maximal specific activity of D-carnitine decomposition of 47.05 unit/mg cell. The cells were frozen at $-80^{\circ}C$ to assess functions as enzyme sources. Optimal concentration of cells and DL-carnitine were 17 g/$\ell \; and \; 20 g/\ell$, respectively, and reaction buffer was best at 75 mM of Tris. HCl. Optimal temperature and pH were $36^{\circ}C$ and 8.2, respectively. When the reaction at optimal conditions was carried out for 14 h, the optical purity was 98.21 %, and the quantity and yield of remaining L-carnitine were 4.432 g/$\ell$ and 44.32%, respectively.

• 한국식품과학회지
• /
• 제47권1호
• /
• pp.95-102
• /
• 2015

본 연구는 분유모델시스템에 $\small{L}$-carnitine, pyridoxine hydrochloride, $\small{DL}$-${\alpha}$-tocopheryl acetate를 첨가하여 Maillard 반응에 의해 생성된 MRPs를 저감화 시키기 위한 최적조건을 찾기 위해 RSM의 CCD를 이용하였다. $\small{L}$-Carnitine ($X_1$), pyridoxine hydrochloride($X_2$), $\small{DL}$-${\alpha}$-tocopheryl acetate ($X_3$)의 농도를 독립변수로 하고 형광도와 HMF 함량을 종속변수로 각각 설정하였다. 종속변수 회귀식의 결정계수($R^2$)는 각각 0.942, 0.861로 반응표면분석 모델에 적합하였다. 형광도와 HMF 함량은 $\small{L}$-carnitine과 pyridoxine hydrochloride의 농도가 낮을 때 $\small{DL}$-${\alpha}$-tocopheryl acetate의 농도가 감소할수록 그 값이 급격히 감소하였다. $\small{L}$-Carnitine의 농도가 높을 때 pyridoxine hydrochloride의 농도가 $20{\mu}M$ 이하로 감소할수록 형광도가 감소하였고 HMF 함량은 $\small{L}$-carnitine의 농도에 관계없이 pyridoxine hydrochloride의 농도가 $20{\mu}M$ 이하로 감소할수록 감소하는 경향을 나타냈다. 본 실험에서 분유모델시스템에서 생성된 MRPs를 저감화 할 수 있는 최적조건으로 $\small{L}$-carnitine, pyridoxine hydrochloride, $\small{DL}$-${\alpha}$-tocopheryl acetate의 농도는 각각 2.26, 15.77, $20.63{\mu}M$이었다. 이때 형광도는 77.4%였고 HMF 함량은 248.7 ppb로 각각 유단백질-유당 마이얄 반응생성물(LC, lactose+sodium caseinate)대비 MRPs를 22.6, 23.1% 감소시킬 수 있다고 예측할 수 있었다. 또한, RSM을 통해 찾은 최적 조건의 실험값으로 형광도는 79.3%였고 HMF 함량은 247.6 ppb로 각각 LC대비 MRPs를 20.7, 17.8% 감소 시켰다. 따라서, $\small{L}$-carnitine, pyridoxine hydrochloride, $\small{DL}$-${\alpha}$-tocopheryl acetate의 최적화된 혼합을 통하여 분유 제조 시 MRPs 생성을 저감화 시킬 수 있을 것으로 생각된다.

• Journal of Nutrition and Health
• /
• 제36권5호
• /
• pp.483-490
• /
• 2003

Chitosan, hydroxycitrate and L-carnitine have been known to be antiobesity components. The purpose of this study was to evaluate the combined effects of chitosan, hydroxycitrate and L-carnitine mixture as a potential antiobesity supplement in overweight women. Pre-menopausal healthy females who were overweight (percent ideal body weight > 110) were included in this study. Forty-nine subjects randomly received a placebo (n = 25) or antiobesity-supplement (n = 24), which was a mixture of chitosan, hydroxycitrate, and L-carnitine. Before and after the eight-week experimental period, anthropometric parameters, blood components and computerized tomography were measured. At baseline, the two groups were well matched in terms of age, body mass index and lipid profile. After the eight weeks of potential antiobesity supplementation, the subjects' body fat percent had decreased significantly (p < 0.001) by 5.6% (39.1 $\pm$ 1 vs 36.9 $\pm$ 1%) while lean body mass increased (p < 0.01). Vsceral fat area at the L4 vertebra decreased significantly (p < 0.01) by 8.6% in the supplemented group and the total fat area at the L4 vertebra showed a tendency to decrease (p = 0.051) by 2.4%. Also, in the group given the antiobesity-supplement rather than the placebo, the fasting triglyceride level decreased significantly (p < 0.05) by 10.0%. In addition, serum total cholesterol levels in the antiobesity-supplement group showed a tendency to decrease (p=0.159) by 2.7% (194 $\pm$ 6 vs 189 $\pm$ 6 mg/dl). No side effects were found in either group during the intervention. In conclusion, the present study demonstrated that taking a mixture of chitosan, hydroxycitrate, and L-carnitine as a potential antiobesity supplement for eight weeks produced advantageous changes in the weight and visceral fat accumulation of overweight women without any side effects. (Korean J Nutrition 36(5): 483~490, 2003)